Topical imiquimod 5% as an alternative therapy in periocular basal cell carcinoma in two patients with surgical contraindication
Arch Soc Esp Oftalmol. 2017 Feb;92(2):93-96.
doi: 10.1016/j.oftal.2016.07.002.
Epub 2016 Sep 3.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Oftalmología, Hospital Universitario Central de Asturias, Oviedo, Asturias, España. Electronic address: m.c.c.a.carmen@gmail.com.
- 2 Servicio de Oftalmología, Hospital Universitario Central de Asturias, Oviedo, Asturias, España.
Abstract
Clinical cases:
The cases are presented of two patients with periocular basal cell carcinoma of the eyelid who received topical imiquimod 5%, with a good response. Both had a functional state that contraindicated surgical treatment.
Conclusion:
Imiquimod cream 5% was shown to be an effective alternative to surgical treatment of periocular basal cell carcinoma, especially in those cases where surgery is not possible.
Keywords:
Basal cell carcinoma; Carcinoma basocelular; Casos desfavorables; Imiquimod; Periocular tumors; Topical treatment; Tratamiento tópico; Tumores perioculares; Unfavourable cases.
Copyright © 2016 Sociedad Española de Oftalmología. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Acquired Immunodeficiency Syndrome / complications
-
Aminoquinolines / adverse effects
-
Aminoquinolines / therapeutic use*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Basal Cell / drug therapy*
-
Contraindications, Procedure
-
Eyelid Neoplasms / drug therapy*
-
HIV-Associated Lipodystrophy Syndrome / complications
-
Humans
-
Imiquimod
-
Male
-
Middle Aged
-
Plastic Surgery Procedures
-
Remission Induction
-
Skin Ulcer / chemically induced
-
Surgical Flaps
Substances
-
Aminoquinolines
-
Antineoplastic Agents
-
Imiquimod